Zolunicant hydrochloride is under clinical development by Mind Medicine MindMed and currently in Phase I for Opium (Opioid) Addiction. According to GlobalData, Phase I drugs for Opium (Opioid) Addiction have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Zolunicant hydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Zolunicant hydrochloride overview
18-Methoxycoronaridine (18-MC) is under development for the treatment of leishmaniasis, substance addictions including cocaine, opiate, methamphetamine, nicotine, alcohol and opioid use disorders. The drug candidate is administered orally. The drug candidate is an alpha-3-beta-4 nicotinic receptor antagonist. It is a new chemical entity.
It was also under development for the treatment of obesity, other forms of compulsive behavior. It is a psychedelic drug.
Mind Medicine MindMed overview
Mind Medicine MindMed (MindMed) is a neuro-pharmaceutical company. It develops, discovers and deploys psychedelic inspired medicines to promote wellness, improve health, and alleviate suffering. MindMed is headquartered in New York, the US.
For a complete picture of Zolunicant hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.